Overview: Proinsulin TestIntroduction: The Proinsulin Test measures proinsulin to diagnose insulinomas or diabetes, causing low blood sugar. Following 2023 Endocrine Society guidelines, it uses biochemical methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in endocrinology for patients with suspected insulinomas or type 2 diabetes.
Other Names: Proinsulin Assay, Insulin Precursor Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Proinsulin testing began in the 1980s with insulinoma research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures proinsulin to diagnose insulinomas or diabetes, guides treatment, and evaluates patients with low blood sugar.
Test Parameters: 1. Proinsulin Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma. Report history of low blood sugar or diabetes symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document low blood sugar, diabetes, or family history of insulinomas. Include current medications, especially insulin or sulfonylureas.
Consent: Written consent required, detailing the tests purpose, insulinoma/diabetes implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to measure proinsulin levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for insulinoma or diabetes diagnosis.
Factors Affecting Result Accuracy: Improper fasting or sample hemolysis can affect results. Medications like sulfonylureas may elevate proinsulin.
Clinical Significance: Elevated proinsulin confirms insulinoma, guiding surgical intervention. Abnormal levels in diabetes guide therapy adjustments.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: C-peptide, insulin levels, or pancreatic imaging to confirm insulinoma or diabetes diagnosis.
Test Limitations: Non-specific for certain metabolic disorders; clinical correlation is needed. Sample quality affects sensitivity.
References: Endocrine Society Insulinoma Guidelines, 2023; Journal of Clinical Endocrinology, Cryer PE, 2022.
